
Contents

Preface	ix
Introduction	xi
Chapter 1. Enzyme Kinetics, Inhibition and Activation	1
1.1. Michaelis and Menten theory	2
1.2. Irreversible inhibitors	3
1.3. Reversible inhibitors in a Michaelian system	4
1.3.1. Reversible competitive inhibitors	4
1.3.2. Reversible non-competitive inhibitors	7
1.3.3. Reversible uncompetitive inhibitors.	11
1.4. Allosteric: inhibitors and activators.	13
1.4.1. Allosteric enzyme kinetics	14
1.4.2. Mechanism of allosteric enzyme regulation	16
1.5. References	17
Chapter 2. Targeted Viral and Microbial Enzymes	19
2.1. Viral targets	20
2.1.1. Herpes group viruses: DNA-dependent DNA polymerases (EC 2).	20
2.1.2. Influenza virus: exo-alpha-sialidase or neuraminidase (EC 3)	21
2.1.3. HIV protease (EC 3)	22
2.1.4. HIV reverse transcriptase (RNA/DNA-dependent DNA polymerase – EC 2)	26
2.1.5. HIV integrase (EC 2).	29
2.1.6. Hepatitis C virus (HCV): RNA-dependent RNA polymerase (NS5B – EC 2) and viral protease (NS3-4A – EC 3)	30

2.2. Bacterial targets	31
2.2.1. Specific target (action mainly focused on the <i>Mycobacterium tuberculosis</i> species)	31
2.2.2. General actions	33
2.3. Fungal targets	64
2.3.1. 1,3-beta-glucan synthase (EC 2)	64
2.3.2. Squalene mono-oxygenase (EC 1)	65
2.3.3. 14-sterol demethylase (EC 1)	65
2.3.4. Thymidylate synthase (EC 2)	66
2.4. Parasite targets	66
2.4.1. Ornithine decarboxylase (EC 4)	66
2.4.2. Heme polymerase (EC 2)	67
2.5. References	67
Chapter 3. Targeted Human Enzymes	71
3.1. Treatment via effectors	71
3.1.1. Ophthalmology	71
3.1.2. Neurology	73
3.1.3. Metabolism and endocrinology	79
3.1.4. Cardiovascular and immunology	94
3.1.5. Oncology	115
3.1.6. Phosphatome and Kinome	131
3.2. Enzyme replacement therapy	143
3.2.1. Gout	143
3.2.2. Acute leukemia and non-Hodgkin's lymphoma	144
3.2.3. Hypophosphatasia	144
3.2.4. Chronic obstructive pulmonary disease	144
3.3. References	144
Chapter 4. What are the New Targets?	151
4.1. Inhibition and activation strategies: advantages, disadvantages and current status	151
4.1.1. Irreversible inhibitors	152
4.1.2. Competitive inhibitors	153
4.1.3. Non-competitive inhibitors	155
4.1.4. Uncompetitive inhibitors	156
4.1.5. Allosteric effectors	156
4.1.6. Other strategies	157
4.2. Exogenous and endogenous targets	157
4.2.1. Exogenous targets	158
4.2.2. Endogenous targets	162

4.3. Rare diseases and enzymes	166
4.3.1. Lysosomal storage diseases	167
4.3.2. Other rare genetic diseases linked to one or more enzymes	176
4.4. References	176
Chapter 5. Which “New” Drugs are We Moving Towards Now?	181
5.1. Chemistry	181
5.1.1. Combinatorial chemistry	181
5.1.2. Vectorization	182
5.2. Biology	183
5.2.1. Inducers and repressors	184
5.2.2. Antibodies	184
5.3. Genetics	186
5.3.1. Gene therapy	186
5.3.2. Antisense strategies	193
5.4. References	194
Conclusion	197
Index	201